(Q85076690)

English

Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours

scientific article published on 12 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Beate Schultheis

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Thomas C Gauler

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Vesile Schneider

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Dirk Strumberg

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Wilfried E E Eberhardt

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Stephanie Le Scouiller

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Marcelo Marotti

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Kathryn H Brown

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Joachim Drevs

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

12 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1962-1971

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21989836%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

https://scigraph.springernature.com/pub.10.1007/s10637-011-9754-x

0 references

Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VEGF-targeted therapy: therapeutic potential and recent advances

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of Src in solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of Src expression and activation in human cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21989836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q85076690&oldid=2035174103"